Could a light therapy trick make low-dose radiation more effective against tough tumors?
NCT ID NCT04381806
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This early-phase study tests a combination of low-dose radiation and a drug called 5-aminolevulinic acid (ALA) for people with advanced solid tumors that have stopped responding to standard treatments. ALA is thought to collect in cancer cells and make them more sensitive to radiation, potentially allowing lower doses to work while sparing healthy tissue. The main goal is to find the safest dose level, and the study is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
Conditions
Explore the condition pages connected to this study.